To the full analysis
Option Care Health stock: growth
OPCHOption Care Health reported $5.65B in revenue for fiscal 2025, up 13% on the prior year, up 13.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
8.7%
per year from 2006 to 2025, per share −6.4%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 13.3% | 19.1% | 8.7% |
| Revenue per share | 15.8% | −4.8% | −6.4% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | 16.7% | no data | no data |
| Free cash flow per share | 19.3% | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $1.15B | −$38.29M | −$35.3M |
| 2007 | $1.2B | $3.32M | $18.66M |
| 2008 | $1.4B | −$74.03M | −$16.21M |
| 2009 | $1.33B | $54.1M | $17.01M |
| 2010 | $430.71M | −$69.14M | −$32.53M |
| 2011 | $554.51M | $7.87M | $17.53M |
| 2012 | $593.45M | $64.71M | $15.9M |
| 2013 | $696.47M | −$69.65M | −$80.2M |
| 2014 | $922.65M | −$147.47M | −$45.25M |
| 2015 | $982.22M | −$300.13M | −$76.29M |
| 2016 | $935.59M | −$42.77M | −$44.85M |
| 2017 | $817.19M | −$64.2M | −$9.44M |
| 2018 | $1.94B | −$6.12M | −$33.98M |
| 2019 | $2.31B | −$75.92M | $11.18M |
| 2020 | $3.03B | −$8.08M | $100.52M |
| 2021 | $3.44B | $139.9M | $182.94M |
| 2022 | $3.94B | $150.56M | $232.19M |
| 2023 | $4.3B | $267.09M | $329.43M |
| 2024 | $5B | $211.82M | $287.79M |
| 2025 | $5.65B | $207.59M | $217.14M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 22 Nov 2024)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.